Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 4/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.43 |
| ▸ | ATG7 | O95352 | 10/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232107 | 0.90 | ADK (0.36) | ADKADORA3ATG7ADORA1HSPA5 | |
| SCHEMBL15459909 | 0.85 | LMNA (0.42) | ADORA3ADORA1HSPA5 | |
| SCHEMBL17752033 | 0.85 | LMNA (0.42) | ADORA3ADORA1HSPA5 | |
| SCHEMBL17752030 | 0.83 | ADORA2A (0.32) | ADORA3ATG7 | |
| SCHEMBL14928561 | 0.81 | EHMT1 (0.31) | — | |
| SCHEMBL15868469 | 0.81 | EHMT1 (0.31) | — | |
| SCHEMBL15249079 | 0.81 | EHMT1 (0.31) | — | |
| SCHEMBL14946054 | 0.81 | EHMT1 (0.31) | — | |
| SCHEMBL18852307 | 0.81 | EHMT1 (0.31) | — | |
| SCHEMBL15702886 | 0.81 | P2RY2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624249-B2 | Nucleoside kinase bypass compositions and methods | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | DCK, DTYMK, TK1 | ADK 9/4885ADORA3 1004/4885ATG7 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.